News
Public · Published
Canaccord Genuity maintains HealthStream at Hold, raises price target to $32 from $29
Canaccord Genuity kept its Hold rating on HealthStream and raised its price target to $32 from $29, a 10.3% increase. The target implies 1.5% downside from HealthStream's Nov. 4 closing price of $32.48.
Published:
Updated:
What happened
Canaccord Genuity kept its Hold rating on HealthStream and raised its price target to $32 from $29, a 10.3% increase. The target implies 1.5% downside from HealthStream’s Nov. 4 closing price of $32.48.
Confirmed
Global impact / market context
The higher target signals a modestly more favorable valuation view, but the unchanged Hold rating indicates Canaccord did not shift its overall stance. Because the target is slightly below the stated closing price, the update does not imply expected share-price gains from that reference point.
Analyst inference
This is an analyst estimate rather than a reported change in HealthStream’s business, revenue, or costs. A price target is an analyst’s estimate of a share’s value; its rise may influence investor expectations, but the article gives no evidence of a market reaction.
Analyst inference
What to watch
- Watch for later analyst updates that change either the Hold rating or the $32 target; the article provides no new operating results to explain this revision. Analyst inference
- Compare future reported business results with the assumptions behind the higher target, if those assumptions are disclosed; the article does not state Canaccord’s reasoning. Analyst inference
- The cited target is $32 versus a Nov. 4 close of $32.48, implying 1.5% downside; this comparison is confirmed in the article. Confirmed
Evidence
- Original source link unavailable